The present invention relates to pharmaceutical formulations comprising atleast one acid-labile proton pump inhibiting agent and at least one antacid,which have improved bioavailability, chemical stability, physical stability,dissolution profiles, disintegration times, safety, as well as other improvedpharmacokinetic, pharmacodynamic, chemical and/or physical properties. Thepresent invention is directed to methods, kits, combinations, and compositionsfor treating, preventing or reducing the risk of developing a gastrointestinaldisorder or disease, or the symptoms associated with, or related to, agastrointestinal disorder or disease in a subject in need thereof.
